

AUTHOR CONTRIBUTION FORM

Title	Daratumumab-mediated lysis of primary multiple myeloma cells is
	enhanced in combination with the human anti-KIR antibody IPH2102
	and lenalidomide
First author	Inger S. Nijhof

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical 1author.html):

"Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The responsible author of this manuscript confirms that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Responsible author (author responsible for the integrity of the work as a whole)	
Name: Tuna Mutis	
Institute: VU University Medical Center, The Netherlands	
e-mail: t.mutis@vumc.nl	

Author contributions

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, interpretation of data, preparation of the text, etc.):

ISN and BvK executed the experiments, analyzed and interpreted the results. ISN wrote the first draft of the manuscript. JJLvB and PWHIP, PA and YM provided material, assisted in the study design and edited the manuscript. HML and NWCJvdD provided patient material, interpreted the results and edited the manuscript. TM designed the study, interpreted the results and prepared the final draft.